The inhibitors of apoptosis proteins are implicated in promoting cancer cells survival and resistance toward immune surveillance and chemotherapy. Second mitochondria-derived activator of caspases (SMAC) mimetics are novel compounds developed to mimic the inhibitory effect of the endogenous SMAC/DIABLO on these IAPs. Here, we examined the potential effects of the novel SMAC mimetic BV6 on different human cancer cell lines. Our results indicated that BV6 was able to induce cell death in different human cancer cell lines. Mechanistically, BV6 dose dependently induced degradation of IAPs, including cIAP1 and cIAP2. This was coincided with activating the non-canonical NF-kappa B (NF-κB) pathway, as indicated by stabilizing NF-κB-inducing kinase (NIK) for p100 processing to p52. More interestingly, BV6 was able to sensitize some of the resistant cancer cell lines to apoptosis induced by the death ligands tumor necrosis factor-α (TNF-α) and TNF-related apoptosis-inducing ligand (TRAIL) that are produced by different cells of the immune system. Such cell death enhancement was mediated by inducing an additional cleavage of caspase-9 to augment that of caspase-8 induced by death ligands. This eventually led to more processing of the executioner caspase-3 and poly (ADP-ribose) polymerase (PARP). In conclusion, therapeutic targeting of IAPs by BV6 might be an effective approach to enhance cancer regression induced by immune system. Our data also open up the future possibility of using BV6 in combination with other antitumor therapies to overcome cancer drug resistance.
WangSEl-DeiryWS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene2003; 22: 8628–33.
2.
FuldaSDebatinKM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene2006; 25: 4798–811.
3.
NagataS. Apoptosis by death factor. Cell1997; 88: 355–65.
4.
BudihardjoIOliverHLutterMLuoXWangX. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol1999; 15: 269–90.
5.
DuCFangMLiYLiLWangX. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell2000; 102: 33–42.
6.
VerhagenAMEkertPGPakuschMSilkeJConnollyLMReidGEMoritzRLSimpsonRJVauxDL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell2000; 102: 43–53.
7.
RoyNDeverauxQLTakahashiRSalvesenGSReedJC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J1997; 16: 6914–25.
8.
YangYLLiXM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res2000; 10: 169–77.
9.
BertrandMJMilutinovicSDicksonKMHoWCBoudreaultADurkinJGillardJWJaquithJBMorrisSJBarkerPA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell2008; 30: 689–700.
10.
YangYYuX. Regulation of apoptosis: the ubiquitous way. FASEB J2003; 17: 790–9.
11.
MahoneyDJCheungHHMradRLPlenchetteSSimardCEnwereEAroraVMakTWLacasseECWaringJKornelukRG. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA2008; 105: 11778–83.
12.
VarfolomeevEGoncharovTFedorovaAVDynekJNZobelKDeshayesKFairbrotherWJVucicD. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem2008; 283: 24295–9.
13.
HessCJBerkhofJDenkersFOssenkoppeleGJSchoutenJPOudejansJJWaisfiszQSchuurhuisGJ. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol2007; 25: 1209–15.
14.
TammIKornblauSMSegallHKrajewskiSWelshKKitadaSScudieroDATudorGQuiYHMonksAAndreeffMReedJC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res2000; 6: 1796–803.
15.
ChenDJHuertaS. Smac mimetics as new cancer therapeutics. Anticancer Drugs2009; 20: 646–58.
16.
FuldaS. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia2012; 26: 1155–65.
17.
LiLThomasRMSuzukiHDe BrabanderJKWangXHarranPG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science2004; 305: 1471–4.
18.
SunHNikolovska-ColeskaZLuJMeagherJLYangCYQiuSTomitaYUedaYJiangSKrajewskiKRollerPPStuckeyJAWangS. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc2007; 129: 15279–94.
19.
SunHNikolovska-ColeskaZLuJQiuSYangCYGaoWMeagherJStuckeyJWangS. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem2006; 49: 7916–20.
20.
SunHNikolovska-ColeskaZYangCYXuLTomitaYKrajewskiKRollerPPWangS. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem2004; 47: 4147–50.
21.
VarfolomeevEBlankenshipJWWaysonSMFedorovaAVKayagakiNGargPZobelKDynekJNElliottLOWallweberHJFlygareJAFairbrotherWJDeshayesKDixitVMVucicD. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell2007; 131: 669–81.
AmaravadiRKSchilderRJMartinLPLevinMGrahamMAWengDEAdjeiAA. A phase I study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma. Mol Cancer Ther2015; 14: 2569–75.
24.
InfanteJRDeesECOlszanskiAJDhuriaSVSenSCameronSCohenRB. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol2014; 32: 3103–10.
25.
EhrenschwenderMBittnerSSeiboldKWajantH. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis. Cell Death Dis2014; 5: e1570–e1570.
26.
LiWLiBGiacaloneNJTorossianASunYNiuKLin-TsaiOLuB. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol2011; 6: 1801–9.
27.
Muller-SienerthNDietzLHoltzPKappMGrigoleitGUSchmuckCWajantHSiegmundD. SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells. PLoS One2011; 6: e21556–e21556.
28.
WangXLinY. Tumor necrosis factor and cancer, buddies or foes?Acta Pharmacol Sin2008; 29: 1275–88.
29.
LeBlancHNAshkenaziA. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ2003; 10: 66–75.
30.
BrooksADSayersTJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother2005; 54: 499–505.
31.
HofmanovaJVaculovaAHyzd'alovaMKozubikA. Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers. Oncol Rep2008; 19: 567–73.
32.
MitsiadesNMitsiadesCSPoulakiVAndersonKCTreonSP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood2002; 99: 2162–71.
33.
Muhlethaler-MottetABalmasKAudersetKJosephJMGrossN. Restoration of TRAIL-induced apoptosis in a caspase-8-deficient neuroblastoma cell line by stable re-expression of caspase-8. Ann N Y Acad Sci2003; 1010: 195–9.
34.
FuldaS. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. Br J Haematol2009; 145: 441–54.
35.
LaCasseECMahoneyDJCheungHHPlenchetteSBairdSKornelukRG. IAP-targeted therapies for cancer. Oncogene2008; 27: 6252–75.
36.
ObexerPAusserlechnerMJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol2014; 4: 197–197.
37.
BaiLSmithDCWangS. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther2014; 144: 82–95.
38.
Martinez-RuizGMaldonadoVCeballos-CancinoGGrajedaJPMelendez-ZajglaJ. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res2008; 27: 48–48.
39.
HehlgansSOppermannJReichertSFuldaSRodelCRodelF. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiat Oncol2015; 10: 198–198.
40.
BertheletJDubrezL. Regulation of apoptosis by inhibitors of apoptosis (IAPs). Cells2013; 2: 163–87.
41.
CossuFMalvezziFCanevariGMastrangeloELecisDDeliaDSeneciPScolasticoCBolognesiMMilaniM. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1. Protein Sci2010; 19: 2418–29.
42.
DubrezLBertheletJGlorianV. IAP proteins as targets for drug development in oncology. Onco Targets Ther2013; 9: 1285–304.
43.
FuldaSVucicD. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov2012; 11: 109–24.
44.
VallabhapurapuSMatsuzawaAZhangWTsengPHKeatsJJWangHVignaliDABergsagelPLKarinM. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol2008; 9: 1364–70.
45.
ZarnegarBJWangYMahoneyDJDempseyPWCheungHHHeJShibaTYangXYehWCMakTWKornelukRGChengG. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol2008; 9: 1371–8.
46.
ChauhanDAndersonKC. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis2003; 8: 337–43.
47.
ChauhanDNeriPVelankarMPodarKHideshimaTFulcinitiMTassonePRajeNMitsiadesCMitsiadesNRichardsonPZawelLTranMMunshiNAndersonKC. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood2007; 109: 1220–7.
48.
RamakrishnanVPainulyUKimlingerTHaugJRajkumarSVKumarS. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia2014; 28: 1519–28.
49.
Alvarez-FernandezSOrtiz-RuizMJParrottTZaknoenSOcioEMSan MiguelJBurrowsFJEsparis-OgandoAPandiellaA. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res2013; 19: 2677–87.
50.
LiJCaoBZhouSZhuJZhangZHouTMaoX. Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur J Haematol2013; 91: 514–21.
51.
YangMHuangJMaQLXuGXJinJ. Antitumor activity of CDA-, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway. Mol Med Rep2014; 9: 1025–31.
52.
SchimmerADWelshKPinillaCWangZKrajewskaMBonneauMJPedersenIMKitadaSScottFLBailly-MaitreBGlinskyGScudieroDSausvilleESalvesenGNefziAOstreshJMHoughtenRAReedJC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell2004; 5: 25–35.
53.
BakeVRoeslerSEckhardtIBelzKFuldaS. Synergistic interaction of Smac mimetic and IFNalpha to trigger apoptosis in acute myeloid leukemia cells. Cancer Lett2014; 355: 224–31.
54.
CristofanonSAbhariBAKruegerMTchoghandjianAMommaSCalaminusCVucicDPichlerBJFuldaS. Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis. Cell Death Dis2015; 6: e1724–e1724.
55.
LieseJAbhariBAFuldaS. Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells. Cancer Lett2015; 365: 47–56.
56.
MarschallVFuldaS. Smac mimetic-induced upregulation of interferon-beta sensitizes glioblastoma to temozolomide-induced cell death. Cell Death Dis2015; 6: e1888–e1888.
57.
OpelDSchnaiterADodierDJovanovicMGerhardingerAIdlerIMertensDBullingerLStilgenbauerSFuldaS. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. Int J Cancer2015; 137: 2959–70.
58.
SteinwascherSNuguesALSchoenebergerHFuldaS. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. Cancer Lett2015; 366: 32–43.
